Association of time from last known well to alteplase administration and outcomes in acute stroke.
Alteplase
Door-to-needle
Stroke
Thrombolytic
Journal
The American journal of emergency medicine
ISSN: 1532-8171
Titre abrégé: Am J Emerg Med
Pays: United States
ID NLM: 8309942
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
22
04
2021
revised:
08
06
2021
accepted:
09
07
2021
pubmed:
7
8
2021
medline:
21
12
2021
entrez:
6
8
2021
Statut:
ppublish
Résumé
In order to determine if time from onset to treatment time (OTT) to alteplase (tPA) administration is associated with improved outcomes in acute ischemic stroke, we performed a retrospective analysis of all acute ischemic stroke patients who received tPA at our hospital. We performed a retrospective review of our Get With the Guidelines® stroke data to determine OTT was associated with either 1.) modified Rankin scale (mRS) at 90 days or 2.) in hospital hemorrhagic conversion. OTT was examined both as a continuous variable in univariate and multivariate analyses as well as a dichotomous variable with a cutoff of 60 min. We controlled for demographic characteristics, 24 medical history issues, receipt of thrombectomy, and NIH stroke scale at admission. We included 166 patients with data for mRS at 90 days after discharge and 302 patients for hemorrhagic conversion in hospital. In all analyses, there was no difference between OTT in either outcome. Predictors of improved mRS at 90 days included NIH Stroke Scale at admission, age, and lack of hypertension. The only significant predictors for hemorrhagic conversion was NIH stroke scale at admission. Our small, retrospective data shows no association between OTT and either hemorrhagic conversion or mRS at 90 days. This data lends support that time may not be the ideal indicator for identifying patients who will benefit from tPA administration.
Identifiants
pubmed: 34358798
pii: S0735-6757(21)00599-4
doi: 10.1016/j.ajem.2021.07.033
pii:
doi:
Substances chimiques
Fibrinolytic Agents
0
Tissue Plasminogen Activator
EC 3.4.21.68
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
126-128Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Regarding “Association of Time from Last Known Well to Alteplase Administration and Outcomes in Acute Stroke”, Dr. Davis has no conflicts of interest, financial or other, to declare.